Cardiovascular complications in atypical haemolytic uraemic syndrome

被引:53
|
作者
Noris, Marina [1 ]
Remuzzi, Giuseppe [2 ]
机构
[1] IRCCS, Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo e Cele Dacco, I-24020 Bergamo, Italy
[2] Azienda Osped Papa Giovanni XXIII, Unit Nephrol & Dialysis, I-24100 Bergamo, Italy
关键词
FACTOR-H-AUTOANTIBODIES; THROMBOTIC THROMBOCYTOPENIC PURPURA; MEMBRANE COFACTOR PROTEIN; MYOCARDIAL-INFARCTION; PERIPHERAL GANGRENE; CLINICAL CHARACTERISTICS; COMPLEMENT; MUTATIONS; IMPACT; MICROANGIOPATHIES;
D O I
10.1038/nrneph.2013.280
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Haemolytic uraemic syndrome (HUS) is characterized by nonimmune haemolytic anaemia, thrombocytopenia and renal impairment-most incidents in childhood are caused by shiga toxin-producing bacteria. Atypical HUS (aHUS) accounts for 10% of cases and has a poor prognosis. About 60% of patients with aHUS have dysregulation of the alternative complement pathway (complement-mediated aHUS). The kidney is the main target organ, but other organs might also be affected. Cardiac complications occur in 3-10% of patients with complement-mediated aHUS, as a consequence of microangiopathic injury in the coronary microvasculature, and can cause sudden death. Emerging evidence also suggests that either thrombosis or stenosis of the medium and large arteries might complicate disease course, and such disorders occur even after renal function is lost. In this Perspectives article we discuss the impact of cardiovascular involvement in complement-mediated aHUS, the role of acute and chronic complement hyperactivation in such events and the implications for treatment.
引用
收藏
页码:174 / 180
页数:7
相关论文
共 50 条
  • [21] Pregnancy-induced atypical haemolytic uraemic syndrome
    Edwards, Gwenno M.
    Notzing, Jessica
    Frost, Paul
    Pyart, Rhodri
    CLINICAL MEDICINE, 2021, 21 (04) : E403 - E404
  • [22] Early treatment with eculizumab in atypical haemolytic uraemic syndrome
    Garjau, Maria
    Azancot, Maria
    Ramos, Rosa
    Sanchez-Corral, Pilar
    Angeles Montero, Maria
    Seron, Daniel
    CLINICAL KIDNEY JOURNAL, 2012, 5 (01) : 31 - 33
  • [23] Atypical haemolytic uraemic syndrome in a child with cystic fibrosis
    Wong, Matthew D.
    Patel, Chirag
    McTaggart, Steven
    Wainwright, Claire E.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2022, 58 (03) : 532 - 535
  • [24] Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?
    Favre, Guillaume A.
    Touzot, Maxime
    Fremeaux-Bacchi, Veronique
    Hyvernat, Herve
    Gueffet, Jean-Pierre
    Rohrlich, Pierre S.
    Queyrel, Viviane
    Esnault, Vincent
    Fakhouri, Fadi
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) : 802 - 805
  • [25] Eculizumab for atypical haemolytic uraemic syndrome: what next?
    Fadi Fakhouri
    Véronique Frémeaux-Bacchi
    Nature Reviews Nephrology, 2013, 9 : 495 - 496
  • [26] Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
    Wong, Edwin K. S.
    Goodship, Tim H. J.
    Kavanagh, David
    MOLECULAR IMMUNOLOGY, 2013, 56 (03) : 199 - 212
  • [27] Atypical haemolytic-uraemic syndrome in a young patient with renal, neurological, ocular and cardiovascular involvement
    Fredy Nieto-Rios, John
    Maria Sema-Higuita, Lina
    Calle-Botero, Estefania
    Ocampo-Kohn, Ctalina
    Aristizabal-Alzate, Arbey
    Zuluaga-Quintero, Monica
    Zuluaga-Valencia, Gustavo
    NEFROLOGIA, 2016, 36 (01): : 82 - 85
  • [28] Atypical haemolytic uraemic syndrome associated with a hybrid complement gene
    Venables, Julian P.
    Strain, Lisa
    Routledge, Danny
    Bourn, David
    Powell, Helen M.
    Warwicker, Paul
    Diaz-Torres, Martha L.
    Sampson, Anne
    Mead, Paul
    Webb, Michelle
    Pirson, Yves
    Jackson, Michael S.
    Hughes, Anne
    Wood, Katrina M.
    Goodship, Judith A.
    Goodship, Timothy H. J.
    PLOS MEDICINE, 2006, 3 (10) : 1957 - 1967
  • [30] Atypical haemolytic uraemic syndrome and mutations in complement regulator genes
    Dragon-Durey, MA
    Frémeaux-Bacchi, V
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2005, 27 (03): : 359 - 374